May 31, 2024 07:00 AM EDTUpdated 02:15 PM

Neurocrine CEO Kevin Gorman to retire after 32-year run; Bluebird picks up fifth CFO in three years

Alex Hoffman

Copy Chief

Kathy Wong

Editor

Andrew Dunn

Senior Biopharma Correspondent

After more than three decades at Neurocrine, CEO Kevin Gorman will retire later this year, handing the reins of the $13 billion neuroscience drugmaker over …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Neurocrine CEO Kevin Gorman to retire after 32-year run; Bluebird picks up fifth CFO in three years

Alex Hoffman

Copy Chief

Kathy Wong

Editor

Andrew Dunn

Senior Biopharma Correspondent

Sign up to read this article for free.

Despite mixed data in Alzheimer's agitation, Axsome will still seek FDA approval

Ideaya inks ADC deal with $75M upfront; Amylyx, Gubra to develop long-acting GLP-1

WuXi AppTec will sell cell and gene therapy business to private equity firm

BioNTech settles with NIH, UPenn in Covid vaccine disputes and will pay royalties

Califf, on his way out at FDA, predicts agency tug-of-war between Ramaswamy and RFK Jr.

Updated: Flagship gene therapy startup Ring Therapeutics nearly halves workforce as CEO departs

Neu­ro­crine CEO Kevin Gor­man to re­tire af­ter 32-year run; Blue­bird picks up fifth CFO in three years

Copy Chief

Editor

Senior Biopharma Correspondent

Sign up to read this article for free.

more like this

Neurocrine CEO Kevin Gorman to retire after 32-year run; Bluebird picks up fifth CFO in three years